Central Nervous System Expression of a Monoclonal Paraprotein in a Chronic Lymphocytic Leukemia Patient

1992 ◽  
Vol 88 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Phillip Ruiz ◽  
Manijeh Moezzi ◽  
Wilfredo Chamizo ◽  
Parvin Ganjei ◽  
Clarence C. Whitcomb ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

scholarly journals Treatment Sequencing in a Chronic Lymphocytic Leukemia Patient with Central Nervous System Involvement

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Filipa Mousinho ◽  
Tatiana Mendes ◽  
Paula Sousa e Santos ◽  
Maria João Acosta ◽  
José Pereira ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chronic Lymphocytic Leukemia ◽  
Early Stage ◽  
Central Nervous System Involvement ◽  
Rare Condition ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Intrathecal Chemotherapy ◽  
Lymphocytic Leukemia ◽  
The Central Nervous System

Early-stage chronic lymphocytic leukemia (CLL) with neurologic involvement is a rare condition and should require a careful follow-up. Although no standard protocol exists for this condition, intrathecal chemotherapy, combined with systemic chemoimmunotherapy, has been used previously. This case describes the treatment of a patient with CLL and symptomatic compromise of the central nervous system. Our results suggest that a combination of chemotherapy, radiotherapy, and ibrutinib, administered sequentially over a 2-year period, led to a near-complete resolution of the cerebral spinal fluid neoplastic infiltration. Importantly, this response has been maintained with ibrutinib monotherapy for more than 12 months.

Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis

2017 ◽  
pp. 127-138 ◽  
Author(s):  
Eleftheria Polychronidou ◽  
Aliki Xochelli ◽  
Panagiotis Moschonas ◽  
Stavros Papadopoulos ◽  
Anastasia Hatzidimitriou ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Somatic Hypermutation ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

scholarly journals Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882391 ◽  
Author(s):  
Sharad Khurana ◽  
Salman Ahmed ◽  
Victoria R Alegria ◽  
Sonikpreet Aulakh ◽  
Meghna Ailawadhi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Partial Remission ◽  
Single Agent ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Viable Option ◽  
Leukemia Patient ◽  
Therapeutic Landscape ◽  
Response Status ◽  
Anti Cd20

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2.5 years. After retreatment with single-agent obinutuzumab, the patient achieved a partial remission again within one cycle and continues to maintain the response status. This case is a platform for considering obinutuzumab as a viable option for retreatment of chronic lymphocytic leukemia patients who have received it before, similar to the pattern of use for other anti-CD20 monoclonal antibodies in this disease, including rituximab.

Sign in / Sign up

Export Citation Format

Share Document